ArticleCancer journal (Sudbury, Mass.)
Application of proteomics to cancer early detection.
Article in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- A proteomics approach to identify predictive blood biomarkers for pleural mesothelioma in prospective cohorts.Clinical and experimental medicine · 2026Article
- Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives.European journal of medical research · 2025Review
- Nanophotonic sensing and label-free imaging of extracellular vesicles.Light, science & applications · 2025Review
- Structure-changeable luminescent Eu(III) complex as a human cancer grade probing system for brain tumor diagnosis.Scientific reports · 2024Article
- Cross-omics strategies and personalised options for lung cancer immunotherapy.Frontiers in immunology · 2024Review
- C1QA and COMP: plasma-based biomarkers for early diagnosis of pancreatic neuroendocrine tumors.Scientific reports · 2023Article
- New thoughts and findings on invasion and metastasis of pancreatic ductal adenocarcinoma (PDAC) from comparative proteomics: multi-target therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- A Novel NanoMIP-SPR Sensor for the Point-of-Care Diagnosis of Breast Cancer.Micromachines · 2023Article
- The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung Cancer.International journal of molecular sciences · 2023Review
- Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice.Proteomes · 2023Review
- The use of proteomics for blood biomarker research in premature infants: a scoping review.Clinical proteomics · 2021Article
- Application of Proteomics in Cancer: Recent Trends and Approaches for Biomarkers Discovery.Frontiers in medicine · 2021Review
- Ovarian Cancer: Tumor-Specific Urinary Micro-Peptides Profiling as Potential Biomarkers for Early Diagnosis.Proteomes · 2020Article
- Proteomic analysis enables distinction of early- versus advanced-stage lung adenocarcinomas.Clinical and translational medicine · 2020Article
- The Relevance of Mass Spectrometry Analysis for Personalized Medicine through Its Successful Application in Cancer "Omics".International journal of molecular sciences · 2019Review
- Risk assessment for indeterminate pulmonary nodules using a novel, plasma-protein based biomarker assay.Biomedical research and clinical practice · 2018Article
- Analytical validation of a novel multi-analyte plasma test for lung nodule characterization.Biomedical research and reviews · 2018Article
- From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology.High-throughput · 2018Review
- The role of biomarkers in the management of epithelial ovarian cancer.Expert review of molecular diagnostics · 2017Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Strategies to achieve personalized medicine and improve public health encompass assessment of an individual's risk for disease, early detection, and molecular classification of disease resulting in an informed choice of the most appropriate treatment instituted at an early stage of disease development. An unmet need in this field for which proteomics is well suited to make a major contribution is the development of blood-based tests for early cancer detection. This is illustrated in proteomic studies of epithelial cancer that encompass analysis of specimens collected both at the time of diagnosis and specimens collected before onset of symptoms that are particularly suited for the identification of early detection markers. This overarching effort benefits from the availability of plasmas from subject cohorts and of engineered mouse models that are sampled at early stages of tumor development. Integration of findings from plasma with tumor tissue and cancer cell proteomic and genomic data allows elucidation of signatures in plasma for altered signaling pathways. The discovery and further development of early detection markers take advantage of the availability of in-depth quantitative proteomics methods and bioinformatics resources for data mining.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.